GPR17

GPR17 (also known as RWT020016) is a first-in-class, orally active, brain-penetrant small molecule GPR17 antagonist being developed by Rewind Therapeutics for the treatment of demyelinating diseases, including multiple sclerosis, optic neuritis, and nerve injuries. GPR17 (G protein-coupled receptor 17) is a key regulator of oligodendrocyte precursor cell (OPC) maturation. Chronic upregulation of GPR17 in OPCs following myelin injury halts their differentiation into mature, myelin-producing oligodendrocytes. By selectively blocking GPR17, the drug releases this differentiation block, promoting OPC maturation and facilitating structural and functional remyelination. The program is currently in preclinical development.

Other names

GPR17 antagonistGPR-17 antagonistGPR 17 antagonistGPR17 inhibitorGPR-17 inhibitorGPR 17 inhibitorGPR17 modulatorGPR-17 modulatorGPR 17 modulator